By Jacob Gronholt-Pedersen COPENHAGEN (Reuters) -Four patients in Denmark, who experienced vision loss after using Novo ...

Four patients who developed a serious eye disease after using Novo Nordisk A/S’s blockbuster weight-loss drugs have been granted compensation in Denmark, the drugmaker’s home market.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Four patients in Denmark will receive compensation after developing serious eye conditions from the weight-loss and diabetes ...

A Novo Nordisk challenge has driven Regen Doctors to voluntarily discontinue compounded semaglutide product claims, adding to ...

Four people in Denmark who developed serious eye conditions after using popular weight-loss and diabetes drugs Wegovy and ...

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...

More than 40 people sought reimbursement after they said they had developed a serious eye condition as a result of using the ...

Four Danish patients who experienced vision loss after using Novo Nordisk's Wegovy and Ozempic were awarded compensation ...

Microdoses of weight loss drugs like Ozempic may slow down ageing and help increase longevity, a new study suggests.

The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and diabetes treatment Mounjaro.